StemRIM

StemRIM, a biotechnology company researches and develops regeneration-inducing medicine in Japan and globally. The company offers TRIM2, a peptide drug, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, myocardial infarction/cardiomyopathy, liver cirrhosis, and knee osteoarthritis

Pre-clinical stage products, including TRIM3 and TRIM4 for the treatment of various tissue damage diseases; and TRIM5, a molecule for tissue repair SR-GT1, a stem cell gene therapy. Incorporated in 2006, the company is headquartered in Ibaraki, Japan.